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lian subject having a pathological condition involving 
neovascularization by administration in vivo of nanoceria 
particles (cerium oxide nanoparticles) to the subject. The 
method of the invention is useful, for example, for reducing, 
treating, reversing or inhibiting neovascularization in ocular 
tissue such as the retina, macula or cornea; in skin; in synovial 
tissue; in intestinal tissue; or in bone. In addition, the method 
of the invention is useful for reducing or inhibiting neovas-
cularization in a neoplasm (tumors), which can be benign or 
malignant and, where malignant, can be a metastatic neo-
plasm. As such, the invention provides compositions, which 
contain nanoceria particles and are useful for reducing, treat-
ing, reversing or inhibiting angiogenesis in a mannnalian 
subject. 
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INHIBITION OF NEOVASCULARIZATION BY 
CERIUM OXIDE NANOPARTICLES 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
The present application claims the benefit under 35 U.S.C. 
119(e) of U.S. Provisional Application Ser. No. 61/125,602, 
filed Apr. 25, 2008, the entirety of which is hereby expressly 
incorporated herein by reference. 
The present application is also a continuation-in-part of 
U.S. Ser. No. 11/412,665, filed Apr. 27, 2006, now U.S. Pat. 
No. 7,727,559 issued on Jun. 1, 2010, which claims the ben-
efit under 35 U.S.C. § 119( e) of U.S. Provisional Application 
Ser. No. 60/716,630, filedSep.13, 2005, and U.S. Provisional 
Application Ser. No. 60/676,043, filed Apr. 29, 2005. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
Not applicable. 
BACKGROUND OF THE INVENTION 
Angiogenesis (also referred to herein as neovasculariza-
tion) is the process whereby new blood vessels are formed. 
Angiogenesis occurs normally during embryogenesis and 
development, and occurs in fully developed organisms during 
wound healing and placental development. In addition, 
angiogenesis occurs in various pathological conditions, 
including in ocular diseases such as diabetic retinopathy and 
macular degeneration due to neovascularization, in condi-
tions associated with tissue inflammation such as rheumatoid 
arthritis and inflammatory bowel disease, and in cancer, 
where blood vessel formation in the growing tumor provides 
oxygen and nutrients to the tumor cells, as well as providing 
a route via which tumor cells metastasize throughout the 
body. Since millions of people around the world are afflicted 
2 
abnormal migration and proliferation of endothelial cells into 
tissues of the eye. Such neovascularization in ocular tissues 
can induce corneal scarring, retinal detachment and fluid 
accumulation in the choroid, each of which can adversely 
affect vision and lead to blindness. 
Angiogenesis also is associated with the progression and 
exacerbation of inflammatory diseases, including psoriasis, 
rheumatoid arthritis, osteoarthritis, and inflammatory bowel 
diseases such as ulcerative colitis and Crohn's disease. In 
10 inflammatory arthritic disease, for example, influx of lym-
phocytes into the region surrounding the joints stimulates 
angiogenesis in the synovial lining. The increased vascula-
ture provides a means for greater influx of leukocytes, which 
facilitate the destruction of cartilage and bone in the joint. 
15 Neovascularization that occurs in inflammatory bowel dis-
ease results in similar effects in the bowel. 
The growth of capillaries into atherosclerotic plaques in the 
coronary arteries represents another pathological condition 
associated with growth factor induced angiogenesis. Exces-
20 sive blood flow into neovascularized plaques can result in 
rupture and hemorrhage of the blood-filled plaques, releasing 
blood clots that can result in coronary thrombosis. 
The involvement of angiogenesis in such diverse diseases 
as cancer, ocular disease and inflammatory diseases has led to 
25 an effort to identify methods for specifically inhibiting angio-
genesis as a means to treat these diseases. For cancer patients, 
such methods of treatment can provide a substantial advan-
tage over currently used methods such as chemotherapy, 
which kill or impair not only the target tumor cells, but also 
30 normal cells in the patient, particularly proliferating normal 
cells such as blood cells, epithelial cells, and cells lining the 
intestinal lumen. Such non-specific killing by chemothera-
peutic agents results in side effects that are, at best, unpleas-
ant, and can often result in unacceptable patient morbidity, or 
35 mortality. In fact, the undesirable side effects associated with 
cancer therapies often limit the treatment a patient can 
receive. 
by these diseases, a considerable effort has been made to 
understand the mechanisms involved in angiogenesis in the 40 
hope that such an understanding will allow the development 
For other pathological conditions associated with abnor-
mal angiogenesis such as diabetic retinopathy, there are no 
effective treatments short of retinal transplants. However, 
even if retinal transplantation is performed, the new retina 
of methods for detecting and inhibiting such undesirable 
angiogenesis. 
Angiogenesis occurs in response to stimulation by one or 
more known growth factors, and also may involve other as yet 
unidentified factors. Endothelial cells, which are the cells that 
line mature blood vessels, normally do not proliferate. How-
ever, in response to an appropriate stimulus, the endothelial 
cells become activated and begin to proliferate and migrate 
into unvascularized tissue forming new blood vessels. In 
some cases, precursor cells can be activated to differentiate 
into endothelial cells which form new blood vessels. 
Blood vessels are surrounded by an extracellular matrix. In 
addition to stimulation by growth factors, neovascularization 
depends on interaction of the endothelial cells with the extra-
cellular matrix, as well as with each other. The activation of 
endothelial cells by growth factors and the migration into and 
interaction with the extracellular matrix and with each other is 
dependent on cell surface receptors expressed by the endot-
helial cells. These cell surface receptors, which include 
growth factor receptors and integrins, interact specifically 
with particular molecules. 
In pathological conditions such as age-related macular 
degeneration and diabetic retinopathy, decreasing availability 
of oxygen to the retina results in a hypoxic condition that 
stimulates the secretion of angiogenic growth factors such as 
vascular endothelial growth factors (VEGF), which induce 
would be subject to the same conditions that resulted in the 
original retinopathy. Thus, there exists a need for novel meth-
ods of inhibiting and treating neovascularization in patients 
45 suffering from pathological conditions characterized by this 
condition. The present invention satisfies this need and pro-
vides related advantages as well in the treatment of other 
disease conditions identified herein. 
The retina is the part of the eye that is sensitive to light. The 
50 macula lutea is the region of the retina that allows us to read 
and recognize faces. Diseases of the macula, such as age-
related macular degeneration (AMD) and diabetic macular 
edema, account for a major proportion of legal blindness. To 
combat these diseases, a variety of accepted and experimental 
55 medications are employed via systemic routes or local, inva-
sive surgical procedures. 
Diabetic retinopathy (DR), a leading cause of blindness in 
type 1 and type 2 diabetics, is a complication of diabetes 
which produces damage to the blood vessels inside the retina. 
60 Diabetic retinopathy can have four stages: (1) mild nonpro-
liferative retinopathy, wherein microaneurysms in the reti-
na's blood vessels occur; (2) moderate nonproliferative ret-
inopathy, wherein some blood vessels feeding the retina 
become blocked; (3) severe nonproliferative retinopathy, 
65 wherein many blood vessels to the retina are blocked, depriv-
ing several areas of the retina with their blood supply; and ( 4) 
proliferative retinopathy, wherein new, abnormal, thin-
US 8,703,200 B2 
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walled and fragile-walled blood vessels grow to supply blood 
to the retina, but which new blood vessels may leak blood to 
produce severe vision loss and blindness. Hemorrhages can 
occur more than once, often during sleep. Fluid can also leak 
into the center of the macula at any stage of diabetic retin-
opathy and cause macular edema and blurred vision. About 
40 to 45 percent of Americans diagnosed with diabetes have 
some stage of diabetic retinopathy, and about half of the 
people with proliferative retinopathy also have macular 
edema. 10 
Macular degeneration is a degeneration of the macular 
region of the retina in the eye. Degeneration of the macula 
causes a decrease in acute vision and can lead to eventual loss 
of acute vision. The wet form of macular degeneration is 
15 
related to abnormal growth of blood vessels in the retina that 
can leak blood and can cause damage to photoreceptor cells. 
Age-related macular degeneration is a collection of clinically 
recognizable ocular findings that can lead to blindness. Macu-
4 
read in dim light or to see sufficient detail to permit a person 
to drive an automobile safely at night. 
A contributing and indicating factor of advanced macular 
degeneration is neovascularization of the choroid tissue 
underlying the photoreceptor cells in the macula. Healthy 
mature ocular vasculature is normally quiescent and exists in 
a state of homeostasis in which a balance is maintained 
between positive and negative mediators of angiogenesis in 
development of new vasculature. Macular degeneration, par-
ticularly in its advanced stages, is characterized by the patho-
logical growth of new blood vessels in the choroid underlying 
the macula. Angiogenic blood vessels in the subretinal chor-
oid can leak vision obscuring fluids, leading to blindness. 
The major causes of blindness in the United States are 
glaucoma, AMD, cataracts, DR, and retinitis pigmentosa 
(RP) which translates into more than 38 million citizens hav-
ing some form of an age related eye disease. In developed 
countries, cataracts are routinely surgically removed and 
20 vision is restored with the insertion of an artificial lens. There lar degeneration is a group of diseases. There are two basic 
types of macular degeneration, including "wet" and "dry". In 
wet macular degeneration, there is an abnormal growth of 
new blood vessels (neovascularization). These new blood 
vessels break and leak fluid, causing damage to the central 
retina. This form of macular degeneration is often associated 25 
with aging. Approximately 85% of macular degeneration 
cases are dry macular degeneration. Vision loss can result 
from the accumulation of deposits in the retina called druzen, 
and from the death of photoreceptor cells in the retina. This 
process can lead to thinning and drying of the retina. 
are no cures for most forms of the other blinding diseases, the 
severity of which increases with age and dramatically 
decreases the quality of life for these patients. Even for 
patients with an inherited blindness, such as RP, vision wors-
ens with age. Nearly 1 out of3 individuals over the age of75 
will develop some form of AMD and with the aging of the 
"Baby Boomers" generation, this means a dramatic increase 
in patient numbers. Nearly 200,000 individuals in the USA 
develop AMD each year. About 2 million Americans over the 
30 age of 40 have significant vision loss due to AMD while an 
additional 8 million have a high risk of vision loss. DR has 
some symptoms very similar to wet AMD including neovas-
cular growth in the eye and sub foveal macular edema. About 
The findings of AMD include the presence of druzen, reti-
nal pigment epithelial disturbance, including pigment clump-
ing and/or dropout, retinal pigment epithelial detachment, 
geographic atrophy, subretinal neovascularization and disci-
form scar. Age-related macular degeneration is a leading 35 
cause of presently incurable blindness, particularly in persons 
over 55 years of age. Approximately one in four persons age 
4 million Americans age 40 and older have DR and >80% of 
patients who have diabetes for more than ten years will 
develop DR. Further, because Native American Indians 
develop diabetes at a much higher rate than the general popu-
lation, DR is becoming a progressively increasing problem in 
states such as Oklahoma which have large numbers of Native 
65 or over have signs of age-related maculopathy, and about 
7% of persons age 75 or over have advanced macular degen-
eration with vision loss. 40 Americans. The annual economic cost to the USA for adult 
Druzen are opthalmoscopically visible, yellow-white hya-
line excrescences or nodules ofBruch's membrane. Bruch's 
membrane lies beneath the retina and the adjacent retina 
pigment epithelium layer. Fat accumulates in Bruch's mem-
brane with age and may contribute to the formation of druzen. 45 
Druzen can occur in two forms. One form comprises hard, 
small (less than about 60 micrometers in diameter) objects 
which do not increase with age and which do not predispose 
to macular degeneration. Another form comprises soft, large 
(more than about 63 micrometers in diameter) objects which 50 
enlarge and become confluent with age. The soft, large druzen 
may predispose to macular degeneration, and are commonly 
seen in eyes of people with advanced macular degeneration in 
at least their other eye. 
Druzen may be metabolic waste products from various 55 
layers of the retina such as from the retina, retina pigment 
epithelium, and choriocapillaris. Druzen may be yellow, 
white, gray, retractile, and/or pink. Druzen may be small, 
medium or large in size. Druzen may be regular or irregular, 
or symmetrical or asymmetrical in shape. A patient who has 60 
druzen and who suffers complications in one eye may suffer 
no complications in the other eye. Complications may com-
prise one or more conditions selected from the group consist-
ing of retina pigment epithelium atrophy, choroid neovascu-
larization, retina detachment serous, and retina detachment 65 
hemorrhagic. Druzen may affect contrast sensitivity, and may 
reduce the eye's ability to see sufficiently to allow a person to 
vision loss is major at about $50 billion per year. 
As noted above, AMD is classified roughly into two cat-
egories based on the absence or presence of choroidal neovas-
cularizations which grow into the eye. Most patients have the 
dry form (85%) whereas about 15% have the wet form. The 
dry form is characterized by the accumulation of debris 
(druzen) between the retinal pigment epithelia and Bruch's 
membrane which effectively eliminates the benefits of the 
choroidal blood supply to the adjacent photoreceptor cells. 
The dry form can lead to the wet form, but optionally may not, 
and patients may still retain some retinal function throughout 
life. In the wet form, the presence of sub-macular neovascular 
vessels leads to retinal edema, ruptured blood vessels, the 
death of the cones in the macula and eventual blindness. 
Current therapeutic treatments for wet AMD involve intrav-
itreal injections of monoclonal antibodies against Vascular 
Endothelial Growth Factor (VEGF) every 6-8 weeks. There 
are no treatments which have proven successful for dry AMD. 
Recently, a subform of AMD was recognized, called Retinal 
Angiomatous Proliferation (RAP), in which neovascular 
lesions occurred within the photoreceptor cell layer as a result 
of neovessels growing from the retinal vasculature through 
the photoreceptors, the RPE and Bruch's membrane where 
they joined choroidal neovascular tufts. These patients repre-
sent about 15% of the vascular form ofAMD. It is an object of 
the present invention to develop a therapeutic treatment for 
blinding diseases, such as RAP. 
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Mammalian cells produce cellular energy in mitochondria 
by using oxygen to metabolize molecular substrates. The vast 
majority of the products of this oxidative metabolism are 
beneficial while about 3% are highly toxic compounds such 
as singlet oxygen, the hydroxide ion, and hydrogen peroxide. 
These Reactive Oxygen Species (ROS) can react with and 
damage almost any type of molecule within the cell including 
proteins, DNA, RNA and lipids. Another major source of 
intracellular ROS is NADPH oxidase which activates the 
6 
FIG. 9 is a graph showing that nanoceria downregulate 
VEGF in mature VLDLr KO retinas. 
DETAILED DESCRIPTION OF THE INVENTION 
S TAT3 pathway which upregulates retinal VEG F. The normal 10 
antioxidant cellular defenses against ROS include catalytic 
proteins such as superoxide dismutase, heme oxygenase and 
thioredoxin as well as small molecules like glutathione, and 
NADPH. Oxidative stress occurs when the level of ROS 
15 
The present invention provides methods for reducing, 
treating, reversing, or inhibiting neovascularization in a tissue 
of a mammalian subject having a pathological condition 
involving neovascularization by in vivo administration of 
nanoceria particles (cerium oxide nanoparticles) in the sub-
ject. The method of the invention is useful, for example, for 
reducing, treating, reversing or inhibiting neovascularization 
in pathological conditions associated with ocular tissue such 
as the retina, macula or cornea; in skin; in synovial tissue; in 
intestinal tissue; or in bone. In addition, the method of the 
invention is useful for reducing, reversing or inhibiting exceeds the ability of the cells' antioxidant defenses to scav-
enge or destroy them. Because of the close proximity of the 
intra-mitochondrial components to the ROS, it is not surpris-
ing that they bear the brunt of damage from ROS and with 
decreased oxidative phosphorylation they produce less 
energy but more ROS. 
As indicated herein, there are many diseases which result 
neovascularization in neoplasms (tumors), which can be 
benign or malignant and, where malignant, can be metastatic 
neoplasms. As such, the invention provides compositions, 
20 which contain nanoceria particles and are useful for reducing, 
reversing, or inhibiting angiogenesis associated with such 
pathological condition in a mammalian subject. 
The pathological conditions treated by the method of the 
invention include, but are not limited to, those of: the eye, 
25 such as diabetic retinopathy or macular degeneration; the 
skin, such as a hemangioma or psoriasis; a joint, such as 
rheumatoid arthritis or osteoarthritis; or the intestine, such as 
Crohn' s disease or ulcerative colitis; or can be a tumor, which 
in the programmed cell death of photoreceptor cells and 
blindness. These include illnesses which are known to be 
inherited such as retinitis pigmentosa as well as many which 
have a genetic component but which may be environmentally 
induced or are of questionable origin such as diabetic retin-
opathy and AMD. Interestingly, irrespective of the primary 
cause, all of these diseases are thought to share some common 
nodes, including oxidative stress caused by a chronic or acute 30 
rise in ROS and apoptosis. The retina has the highest rate of 
oxygen metabolism, is constantly bombarded with photons of 
light, and is therefore exposed to a higher concentration of 
ROS than any other tissue of the body. Neurodegeneration 
within the retina is not unlike neurodegeneration within other 
areas of the central nervous system. Even in the albino rat 
model of light-induced degeneration of photoreceptor cells, 
initiation of apoptosis proceeds through the intracellular pro-
duction of ROS. Strong evidence that oxidative damage is a 
primary cause of AMD was recently presented by Hollyfield 
can be benign or malignant. 
The present invention further provides methods of reduc-
ing, treating, reversing or inhibiting neovascularization (an-
giogenesis) in a tissue in an individual, by administering to 
the individual the nanoceria particles of the invention, thereby 
reducing or inhibiting angiogenesis in the tissue in the indi-
35 vidual and, consequently, reducing the severity of the patho-
logical condition exhibiting the angiogenesis. The condition 
can be any pathological condition associated with angiogen-
esis, including a neoplasm, which can be a malignant neo-
plasm, for example, a carcinoma such as breast carcinoma, 
40 colon carcinoma, ovarian carcinoma or pancreatic carci-
noma, or a sarcoma, mesothelioma, teratocarcinoma, an 
astrocytoma, glioblastoma, or other neoplasm, including a 
metastatic malignant neoplasm. The agent can be adminis-
tered by various routes, for example, intravenously or directly 
et al. ("Oxidative damage-induced inflammation initiates 
age-related macular degeneration', Nat. Med. 2008; 14: 194-
198). 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG.1 shows photomicrographs of results from four assays 
for ROS and ROS-induced changes in VLDLr Knock Out 
(VLDLr KO) mouse retinas. 
45 into the region to be treated, for example, directly into a 
neoplastic tumor; via eye drops or intravitreal injection, 
where the pathological condition involves the eye; or intra-
synovially, where the condition involves a joint, or via other 
methods as discussed elsewhere herein. 
FIG. 2 is a schematic showing that nanoceria inhibit the rise 50 
in VEGF in retinas ofVLDLr KO mice. Actin was stained as 
Without wishing to be bound by theory, it is believed that in 
the present invention, the reduction, reversal, or inhibition of 
neovascularization in pathological conditions of ocular tissue 
such as retina, macula or cornea; of skin such as occurs with 
psoriasis; ofsynovial tissue; ofbone; orofintestinal tissue; or 
a load control. 
FIG. 3 shows immunofluorescence confocal photomicro-
graphs of retinas to show localization ofVEGF in retinas and 
effects of nanoceria thereon. 
FIG. 4 shows micrographs of VLDLr KO retinal layers 
which show formation of new blood vessels ("bleb" at arrow-
heads). These blebs are reduced by nanoceria treatment. 
FIG. 5 shows cut and flattened eyecups of normal (C57) 
and VLDLr KO mice, with and without treatment with nano-
cena. 
FIG. 6 shows micrographs ofVLDLr KO vascular defects. 
FIG. 7 is a graph showing the effects of treatment with 
nanoceria on numbers of choroidal tufts. 
55 of benign or malignant neoplasms occurs by reducing the 
reactive oxygen species (ROS) in the tissue. 
The term "pathological condition" is used broadly herein 
to mean any abnormal physical or physiological condition 
characterized, at least in part, by neovascularization. Such 
60 pathological conditions include neoplasms, ocular diseases 
such as diabetic retinopathy and macular degeneration asso-
ciated with neovascularization, skin diseases such as psoria-
sis and hemangiomas, gingivitis, arthritic conditions such as 
FIG. 8 is a graph showing that nanoceria treatment causes 65 
regression of retinal vascular lesions which were present prior 
rheumatoid arthritis and osteoarthritis, and inflammatory 
bowel diseases. 
The term "neoplasm" is used broadly herein to mean any 
new, pathological tissue growth. For purposes of the present to treatment. 
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invention, a neoplasm generally results in the formation of a 
tumor, which is characterized, in part, by angiogenesis. A 
neoplasm can be benign, for example, a hemangioma, 
glioma, teratoma, and the like, or can be malignant, for 
example, a carcinoma, sarcoma, glioblastoma, astrocytoma, 
neuroblastoma, retinoblastoma, and the like. The term 
"tumor" is used generally to refer to a benign or malignant 
neoplasm, and the term "cancer" is used generally to refer to 
a malignant neoplasm, which may or may not be metastatic. 
Malignant neoplasms that can be treated using a method of 
the invention include, for example, carcinomas such as lung 
cancer, breast cancer, prostate cancer, cervical cancer, pan-
creatic cancer, colon cancer and ovarian cancer; and sarcomas 
such as osteosarcoma and Kaposi's sarcoma, provided the 
neoplasm is characterized, at least in part, by angiogenesis. 
8 
cutaneously, intraorbitally, intracapsularly, intrasynovially, 
intraperitoneally, intracistemally or by passive or facilitated 
absorption through the skin using, for example, a skin patch 
or transdermal iontophoresis. Furthermore, the composition 
can be administered by injection, intubation, via a supposi-
tory, orally or topically, the latter of which can be passive, for 
example, by direct application of an ointment or powder 
containing the composition, or active, for example, using a 
nasal spray or inhalant. The pharmaceutical composition also 
10 can be incorporated, if desired, into liposomes, microspheres 
or other polymer matrices as discussed elsewhere herein. 
In one embodiment the present invention comprises thera-
peutic treatments which eliminate the leaky neovessels, cho-
15 roidal neovascularization and vascular lesions within the reti-
nas of mammals with RAP and other ocular diseases An individual to be treated using a method of the invention 
can be any individual exhibiting a neovascularization associ-
ated with a pathological condition and, therefore, can be, for 
example, a vertebrate such as a mammal, including a human, 
other primate, dog, cat, horse, cow, sheep, or goat or any other 20 
mammal, particularly a commercially important animal or a 
domesticated animal and any other animal subject to diseases 
similar to those described herein. 
characterized by neovascularization. The present therapeutic 
regimes also slow the progression of photoreceptor cell death, 
for example in all forms of AMD and DR. These treatments 
will dramatically improve the quality of life for millions of 
Americans and correspondingly reduce the $50 billion annual 
economic cost to the USA. 
The present invention in particular relates to methods of 
treatment of macular degeneration associated with subretinal 
25 neovascularization and a proliferation of neovascular tissue 
in the eye of a mammalian subject, and to methods of inhib-
iting or substantially reducing the rate of subretinal neovas-
cularization and proliferation of neovascular tissue in the eye 
Treatment using the methods of the present invention is 
considered to be successful when adverse clinical signs or 
symptoms associated in the subject with the pathological 
condition being treated are reduced, reversed, inhibited, or 
otherwise ameliorated. A reduction in the severity of a patho-
logic condition can be detected by various methods, including 
routine clinical tests such as blood tests, which can used to 30 
determine relevant enzyme levels or circulating antigen or 
antibody; imaging tests, which can be used to detect a 
decrease in the growth rate or size of a neoplasm; or an 
ophthalmic procedure, which can be used to identify a reduc-
tion in the number of blood vessels in the retina of a diabetic 35 
associated with macular degeneration. 
The present invention also relates to methods of treatment 
of diabetic neuropathy, especially diabetic retinopathy asso-
ciated with neovascularization, and to methods of inhibiting 
or substantially reducing the rate of proliferation of neovas-
cular tissue in the eye associated with diabetic neuropathy 
Examples of cerium oxide nanoparticles that may be used 
patient. Such clinical tests are selected based on the particular 
pathological condition being treated. A reduction in the sever-
ity of a pathological condition also can be detected based on 
comments made by the patient being treated, for example, 
that a patient suffering from arthritis feels less pain or has 
greater joint mobility, or that a patient with diabetic retinopa-
thy or with macular degeneration due to neovascularization 
can see more clearly, or the like. 
The nanoceria particle composition of the invention gen-
erally will be in the form of a pharmaceutical composition 
comprising the nanoceria particles and a pharmaceutically 
acceptable carrier. Pharmaceutically acceptable carriers are 
well known in the art and include aqueous solutions such as 
physiologically buffered saline or other buffers or solvents or 
vehicles such as glycols, glycerol, oils such as olive oil or 
injectable organic esters. 
The total amount of the nanoceria composition can be 
administered to a subject as a single dose, over a relatively 
short period of time, or can be administered using a treatment 
protocol in which multiple doses are administered over a 
more prolonged period of time. The concentration and quan-
tity of the nanoceria required in the treatment protocol 
depends on many factors including the age and general health 
of the subject as well as the route of administration, the 
number of treatments to be administered. 
The nanoceria of the present invention which are useful for 
reducing or inhibiting angiogenesis or a pharmaceutical com-
position thereof containing the nanoceria can be used for 
treating any pathological condition that is characterized, at 
least in part, by neovascularization. The nanoceria can be 
administered by various routes including, for example, 
parenterally, including intravenously, intramuscularly, sub-
in the present invention include, but are not limited to, those 
described in U.S. Pat. Nos. 7,347,987 and 7,504,356 (each of 
which are expressly incorporated by reference herein) and 
include, but are not limited to, cerium oxides having the 
40 formulas Ce02 and Ce20y 
The nanoceria particles of the composition are adminis-
tered in one embodiment at concentrations of 1 nM to 1000 
µM, or from 1 nM to 100 µM, or from 1 nM to 10 µM, or from 
1 nM to 1 µM, or from 1 nM to 100 nM, or from 1 nM to 50 
45 nM, or from 1 nM to 10 nM, or from 10 nM to 10 µM, or from 
100 nM to 10 µM. More particularly, the cerium oxide par-
ticles of the present invention are further characterized as 
ultra-fine and are preferably in a size range of from approxi-
mately 1 nanometer in diameter to approximately 10 nanom-
50 eters in diameter; more preferably from approximately 1 nm 
to approximately 7 nm. 
Examples of various methods of administering therapeutic 
compositions to the eye, and which may be used to administer 
the nanoceria of the present invention, are described, for 
55 example, in U.S. Pat. No. 7,442,686, the entirety of which is 
hereby expressly incorporated herein by reference. 
For example, the nanoceria particles may be administered 
by direct injection into the eye, intravenous, intraperitoneal, 
intramuscular, oral or topically on the eye or skin. The nano-
60 ceria will reduce damage to the eye caused by angiogenesis 
ocular pathological conditions including, but not limited to, 
glaucoma, diabetic retinopathy, inherited retinal degenera-
tion (for example, RP), AMD, retinal detachment or any 
disease or event which involves production of ROS, neovas-
65 cularization, for example, including retinopathy of prematu-
rity (ROP), neovascular glaucoma, macular edema, Sickle 
Cell retinopathy, choroidal neovascularization, retinal vascu-
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lar diseases, and ocular oncology. These particles will pre-
serve and prolong vision when administered in vivo. 
Administration of the nanoceria compositions of this 
invention is preferably by injection, such as by injection into 
an eye, preferably into a blood vessel that supplies blood to 
the eye or by microinjection into the macula by first penetrat-
ing the sclera, by topical application such as to a tissue of the 
eye such as the cornea or sclera, or by implantation such as by 
controlled release from a depot or implant comprising a phar-
maceutically acceptable matrix or pharmaceutically accept-
able carrier, which depot or implant is located proximal to the 
tissue of the eye, preferably proximal to or embedded into 
tissue comprising the posterior portion of the eye. A thera-
peutically effective amount of the composition ofthis inven-
tion can be delivered to the choroid and retina proximal to the 
macula of the eye to retard the growth of blood vessels that 
lead to macular degeneration in the eye. 
In one aspect, therapeutic compositions of this invention 
can be administered to the eye or other areas of the body by a 
number of techniques including by use of medical devices 
and methods of administration known in the art, such as for 
example those described in U.S. Pat. Nos. 6,397,849; 6,299, 
895; 5,770,589; 5,767,079; 5,707,643; 5,632,984; 5,443,505; 
5,399,163; 5,383,851; 5,273,530; 5,064,413; 4,941,880; 
4,790,824; 4,596,556; 4,487,603; 4,486,194; 4,475,196; 
4,447,224; 4,447,233; and 4,439,196, each of which is 
expressly incorporated herein by reference in its entirety. 
Many other methods of administration such as a single or 
multiple implant and/or biodegradable matrix composition 
for controlled release the nanoceria of this invention, an 
implantable hydrogel matrix which can be biodegradable, an 
injectable delivery system such as a liposome suspension, 
injection methods such as comprising a needle less syringe or 
cannula or needle and syringe, poorly water soluble and bio-
degradable carriers, and delivery routes that are applicable to 
administer a drug to the eye and to blood vessels that feed 
blood to the eye can be used with the compositions of this 
invention. 
10 
ene-co-vinyl acetate), PVA, partially hydrolyzed poly( ethyl-
ene-co-vinyl acetate), poly( ethylene-co-vinyl acetate-co-
vinyl alcohol), a cross-linked poly(ethylene-co-vinyl 
acetate), a cross-linked partially hydrolyzed poly( ethylene-
co-vinyl acetate), a cross-linked poly( ethylene-co-vinyl 
acetate-co-vinyl alcohol), poly-D,L-lactic acid, poly-L-lactic 
acid, polyglycolic acid, PGA, copolymers of lactic acid and 
glycolic acid, polycaprolactone, polyvalerolactone, poly(an-
hydrides), copolymers of polycaprolactone with polyethyl-
10 ene glycol, copolymers of poly lactic acid with polyethylene 
glycol, polyethylene glycol; fibrin, Gelfoam™ (which is a 
water-insoluble, off-white, nonelastic, porous, pliable gel 
foam prepared from purified gelatin and water for injection), 
and combinations and blends thereof. Copolymers can com-
15 prise from about 1 % to about 99% by weight of a first mono-
mer unit such as ethylene oxide and from 99% to about 1 % by 
weight of a second monomer unit such as propylene oxide. 
Blends of a first polymer such as gelatin and a second polymer 
such as poly-L-lactic acid or polyglycolic acid can comprise 
20 from about 1 % to about 99% by weight of the first polymer 
and from about 99% to about 1 % of the second polymer. 
The term "pharmaceutically acceptable carrier" or "adju-
vant" and "physiologically acceptable vehicle" and the like 
are to be understood as referring to an acceptable carrier or 
25 adjuvant that may be administered to a subject, together with 
nanoceria ofthis invention. Further, as used herein "pharma-
ceutically acceptable carrier" or "pharmaceutical carrier" are 
known in the art and include, but are not limited to, 0.01-0.1 
M solutions and preferably 0.05 M phosphate buffer, or 0.8% 
30 saline. Additionally, such pharmaceutically acceptable carri-
ers may be aqueous or non-aqueous solutions, suspensions, 
and emulsions. Examples of non-aqueous solvents are pro-
pylene glycol, polyethylene glycol, vegetable oils such as 
olive oil, and injectable organic esters such as ethyl oleate. 
35 Aqueous carriers include water, alcoholic/aqueous solutions, 
emulsions or suspensions, including saline and buffered 
media. Parenteral vehicles include sodium chloride solution, 
Ringer's dextrose, dextrose and sodium chloride, lactated 
Ringer's or fixed oils. Intravenous vehicles include fluid and For example, the present invention can be delivered by a 
variety of techniques to the macula region of the eye, prefer-
ably to the posterior segment of the eye proximal to the 
macula. Examples of such techniques include: (a) use of a 
sterile, pharmaceutically acceptable biodegradable scleral 
plug which comprises nanoceria and optionally a pharmaceu-
tically acceptable biodegradable matrix such as a polylactic 45 
acid or polyglycolic acid or a copolymer of lactic acid and 
glycolic acid, which plug can be inserted into the eye via an 
incision in the sclera; (b) use of an implant comprising nano-
ceria of this invention and optionally a pharmaceutically 
acceptable biodegradable matrix wherein the sclera is cut to 50 
expose the suprachoroid and wherein the implant is placed 
into a suprachoroidal space from which implant the nanoceria 
are released, for example, into the vitreous region of the eye; 
40 nutrient replenishers, electrolyte replenishers such as those 
based on Ringer's dextrose, and the like. Preservatives and 
other additives may also be present, such as, for example, 
antimicrobials, antioxidants, collating agents, inert gases and 
the like. 
In addition, the term "pharmaceutically effective amount" 
or "therapeutically effective amount" refers to an amount of 
nanoceria (dose) effective in treating a patient, having, for 
example, a site of neovascularization. It is also to be under-
stood herein that a "pharmaceutically effective amount" may 
be interpreted as an amount giving a desired therapeutic 
effect, either taken in one dose or in any dosage or route or 
taken alone or in combination with other therapeutic agents. 
Advanced wet AMD is a disease of the eye which com-
prises neovascularization of the choroid tissue underlying the 
photoreceptor cells in the macula. As noted above, AMD, 
particularly in its advanced stages, is characterized by the 
( c) use of intravitreal injection into the vitreous body of a 
pharmaceutical composition comprising nanoceria and aster- 55 
ile aqueous carrier; ( d) injection or infusion via a flexible 
cannula that can be inserted through the posterior sclera and 
down into the subretinal space at the posterior region of the 
eye; and ( e) by injection of a pharmaceutical composition 
comprising nanoceria and a pharmaceutically acceptable car- 60 
rier into an avascular region of the sclera to form a depot 
comprising nanoceria within the scleral layer and from which 
the nanoceria can diffuse to the macula, choroid layer, and/or 
retina. 
pathological growth of new blood vessels in the choroid 
underlying the macula. Angiogenic blood vessels in the sub-
retinal choroid can leak vision obscuring fluids, leading to 
blindness. 
In one aspect, diseases of the eye which exhibit neovascu-
larization proximal to the retina such as wet AMD, retinitis 
pigmentosa, Stargardt' s Disease, diabetic retinopathy, hyper-
tensive retinopathy, and occlusive retinopathy can be treated 
In one aspect, a pharmaceutical compositions used in the 
present invention can comprise a pharmaceutically accept-
able carrier selected from the group consisting of poly( ethyl-
65 to reduce the rate of neovascularization by administration of 
a composition of this invention comprising nanoceria having 
angiogenesis inhibiting activity. 
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mulations are used, the nanoceria of the invention and one or 
more additional agents can be administered concurrently, or 
at separately staggered times, i.e., sequentially. The therapeu-
tic methods of the invention may also be combined with other 
agents or medical procedures used for treatment of eye dis-
orders or other pathological conditions expressing neovascu-
larization. 
Nanoceria particles are contemplated herein for use in 
preventing blindness due to a variety of diseases including, 
but not limited to, macular degeneration, hereditary retinitis 
pigmentosa, glaucoma, diabetes, and retinal detachment. 
Investigations of nanocrystalline cerium oxide (e.g., Ce02 
and Ce20 3 ) nanoparticles (nanoceria) have revealed that its 
lattice constant increases with decreasing nanoparticle size. 
The compositions of the present invention when adminis-
tered to the eye or to blood vessels that feed into the eye of a 
patient can be useful to treat ocular diseases such as, but not 
limited to, wetAMD, RP, Stargardt's Disease, DR, hyperten-
sive retinopathy, and occlusive retinopathy by reducing the 
rate of formation ofneovascularization and thereby slow the 
progress of the disease. The rate of neovascularization which 
occurs in such a disease in a patient is preferably reduced by 
administration of the nanoceria of this invention to 90%, more 
preferably to 50%, even more preferably to 25%, even more 10 
preferably to 10%, even more preferably to 5%, even more 
preferably to 1 %, and most preferably to 0.1 % or less of the 
rate of neovascularization which occurs in such a disease in 
the absence of administration of the nanoceria of this inven-
tion (i.e., in an untreated patient). 15 This has been attributed to an increase in oxygen vacancies in 
the crystal structure. This suggests that the migration 
enthalpy of the oxygen vacancy in Ce02 is smaller at the 
nanoscale. Additionally, at the nanoscale, the surface area of 
Ce02 particles is dramatically enlarged in relation to its vol-
Administration of a pharmaceutical composition compris-
ing the nanoceria of this invention to a subject in need of 
treatment for a disease of the eye such as macular degenera-
tion, retinitis pigmentosa, Stargardt's Disease, diabetic retin-
opathy, hypertensive retinopathy, and occlusive retinopathy 
can substantially reduce or prevent angiogenesis associated 
with subretinal neovascularization, choroid neovasculariza-
tion underlying the macula, and a proliferation of neovascular 
tissue in the subretinal choroid proximal to the macula in an 
eye in a mammalian subject. 
The method can be useful as a prophylactic treatment to 
prevent further onset or progression of macular or retinal 
degeneration in an eye that exhibits symptoms of a disease of 
the eye such as macular degeneration, retinitis pigmentosa, 
Stargardt's Disease, diabetic retinopathy, hypertensive retin-
opathy, and occlusive retinopathy. In another aspect, the 
method can be useful as a prophylactic treatment to prevent 
the deposition of druzen and the death of photoreceptor cells 
in the macula or elsewhere in the retina. In one aspect of the 
invention, the method can prevent the death of photoreceptor 
cells (which photoreceptor cells are also herein referred to as 
photoreceptors) in the eye of a subject by acting on intracel-
lular mechanisms of the regulation of cell death. The method 
can also be useful to prevent onset or progression of macular 
degeneration in an eye that does not exhibit vision-obscuring 
symptoms of macular degeneration, especially in an eye of a 
patient whose other eye does exhibit vision-obscuring symp-
toms of macular degeneration. 
In another aspect of this invention, a method of treatment of 
20 ume which increases oxygen exchange and redox reactions. 
Thus, oxygen vacancies are likely to form more readily at the 
nano scale. 
It is believed that nanoceria, owing to their chemical and 
physical structure, can protect cells from ROS or free-radical-
25 induced damage. This is especially supported by the demon-
stration that nanoceria have catalytic activities like those of 
two major anti-oxidative enzymes, super oxide dismutate and 
catalase. The "defects" in the nanoceria particles can act as 
chemical spin traps similar to nitrosone compounds, cur-
30 rently used as biological antioxidants. It is believed that the 
nanoceria act as free-radical scavengers by switching 
between the +3 and +4 valence states via various surface 
chemical reactions and one Ce02 nanoparticle may offer 
many sites of spin-trap activity, whereas current pharmaco-
35 logical agents offer only a few per molecule. Additionally, the 
lattice defects in nanoceria can regenerate and do not neces-
sarily require repetitive dosages as seen with the use of 
dietary supplements of antioxidants such as vitamins C and E. 
It was previously demonstrated that the intravitreal injection 
40 of nanoceria, which catalytically scavenge ROS, prevents 
light damage and blindness in albino rats. Herein we demon-
strate (as described below) that nanoceria catalytically 
destroy ROS in the retinas ofVLDLr Knock Out mice which 
in tum prevent oxidative stress and ROS induced damage 
45 such as increases in VEGF, choroidal neovascularization, 
retinal vascular lesions, degeneration of photoreceptor cells 
and the subsequent loss of vision. 
a disease of the eye such as macular degeneration, retinitis 
pigmentosa, Stargardt' s Disease, diabetic retinopathy, hyper-
tensive retinopathy, and occlusive retinopathy comprises 
administration such as by injection or implantation (or other 
method described herein) into tissue proximal to the eye of a 
therapeutically effective amount of nanoceria of this inven- 50 
ti on, or of a sterile pharmaceutical composition of this inven-
tion suitable for injectable administration and comprising 
nanoceria of this invention and a carrier suitable for injectable 
use (e.g., sterile, sterilizable, and isotonic with blood), which 
can prevent or delay the onset of angiogenesis associated with 55 
subretinal neovascularization, choroid neovascularization 
underlying the macula, and a proliferation of neovascular 
tissue in the subretinal choroid proximal to the macula in an 
eye of a patient. 
Experimental 
The VLDLr KO Mouse Model: 
The Very Low Density Lipid Receptor Knock Out mouse 
(VLDLr KO), (see Heckenlively et al., "Mouse model of 
subretinal neovascularization with choroidal anastomosis". 
Retina 2003; 23: 518-522), is an outstanding animal model 
for AMD and in particular for RAP (Retinal Angiomatous 
Proliferation) in which there is a progressive increase in reti-
nal VEGF and VEGF-induced vascular proliferation within 
the photoreceptor cell outer nuclear layer as well as an accu-
mulation of lipid particles with degeneration of Bruch's 
membrane. This mouse also exhibits subretinal choroidal 
60 neovascularization. Oxidative stress in the VLDLr KO mouse The invention further comprises a combination therapy 
wherein a VEGF inhibitor may be administered in combina-
tion with the present nanoceria therapy. The nanoceria may be 
administered with a cytotoxic agent, a chemotherapeutic 
agent or a growth inhibitory agent can be administered to the 
subject together in a single dosage composition such as a 65 
combined formulation, or each agent can be administered in 
a separate dosage formulation. Where separate dosage for-
has also been shown to be associated with a low antioxidant 
capacity in its mitochondria. The overall phenotype is very 
similar to that associated with a subset of AMD patients who 
have Retina Angiomatous Proliferation (RAP). VEGF is 
responsible for angiogenesis and vasculature formation in the 
eye and numerous strategies have been designed to inhibit its 
activity in many diseases, including AMD and cancer. Cur-
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rently, the only effective therapy for wet AMD is the intrav-
itreal injection, every 4-6 weeks, of monoclonal antibodies 
against VEGF, aptamers which inhibit VEGF activity or 
soluble receptors for VEGF which act as "VEGF traps". Our 
recently published data (Li et al., "Biochemical alterations in 
the retinas of very low-density lipoprotein receptor knockout 
mice: an animal model of retinal angiomatous proliferation". 
Arch Opthalmol 2007; 125: 795-803), demonstrated the rise 
in VEGF in the ONL of the retina, the developmental increase 
14 
These data demonstrate that ROS and ROS-induced effects 
increase in VLDLr KO retinas and that the treatments with 
nanoceria decrease these characteristics. All settings for the 
fluorescence confocal microscope were constant within each 
of the assays. 
The dihydrodichlorofluorescein assay (DCF) visualizes 
cellular oxidation by hydrogen peroxide, peroxynitrite and 
hydroxyl radicals. The data show very low levels of DCF in 
the normal retina (Wt p28), high levels ofDCF in the saline 
injected VLDLr KO retina (v/v p28) and greatly reduced 
levels in the nanoceria (Ce02 ) injected VLDLr retina KO. 
in illicit blood vessels and the increase in pro-inflammatory 10 
enzymes prior to vascularization. We hypothesized herein 
that nanoceria, through scavenging of ROS, can inhibit the 
rise in VEGF, the subsequent angiogenesis and vascular 
lesions in the retina and the eventual photoreceptor cell death. 
Data provided herewith support this assertion. 
In this mouse model (VLDLr KO) for macular degenera-
tion, blood vessels form and grow from the retinal vasculature 
through the choroid and retinal pigment epithelium layer. In 
some forms of macular degeneration and in diabetic retinopa-
thy, the retinal blood vessels also become "leaky". As shown 20 
in the data below, administration of nanoceria particles pre-
vents both choroidal neovascularization (CNV) and leakage 
A major source of intracellular ROS is from the enzyme 
NADPH Oxidase. Our data show that the intensity of staining 
15 
for its activating subunit, P47, is greatly increased in the 
VLDLr KO retina vs the normal control but is reduced almost 
of the retinal blood vessels. 
to control levels by injection of nanoceria. 
Nitrotyrosine is a marker for the intracellular effects of 
Nitrous Oxygen Species. Our data show that the VLDLr KO 
retina stains very intensely whereas the retinas from control 
and nanoceria injected VLDLr KO mice show greatly 
reduced staining. 
ROS-induced damage to DNA is reflected in the amount of 
8-hydroxy-2'-deoxyguanosine (8-0H-dG) present. This 
25 assay requires digestion of the cryostat section with protein-
ase K which results in poor preservation of retinal morphol-
ogy. However the data show that the nanoceria reduce the 
staining for 8-0HdG in the VLDLr KO retinas to near control 
levels. 
We hypothesized that the nanoceria, by a mechanism 
involving the elimination of endogenously produced ROS, 
inhibit the mutant phenotype of the VLDLR -/-mouse. The 
phenotypic characteristics which were measured were: ROS 
and ROS-mediated damage in the retina; the illicit rise in 
Vascular Endothelial Growth Factor (VEGF); retinal vascular 
lesions; subretinal neovascularization; disruption ofBruch's 30 
membrane and the retinal pigment epithelium cell layer by 
choroidal neovascular tufts. Quantitative histology, using 
bright field microscopy on hematoxylin and eosin (H&E) 
stained retinal sections, were used to evaluate the morpho-
logical preservation of photoreceptor cells whereas retinal 35 
function was determined using electroretinography. VEGF 
levels in the retina were assayed with anti-VEGF immunob-
lots, ELISAs and immunocytochemistry whereas its mRNA 
were assayed by RT-PCR. Superoxide radicals in the retina 
were assessed using a hydroxyethidine assay whereas H2 0 2 40 
were assayed with 2',7'-dichloro-dihydro-fluorescein-diac-
etate. ROS-induced damage were visualized with antibodies 
against products of ROS activity including acrolein, nitroty-
rosine and 8-hydroxy-2-deoxy-guanosine. The effects of the 
nanoceria on neuroprotective pathways were analyzed by 45 
Western blots and cDNA micro arrays. We have established a 
vascular filling assay to visualize both the retinal vasculature 
and choroidal neovascularizations. Our new Olympus Zoom 
Fluorescence Microscope (MVXlO) for macro to microfluo-
rescence imaging enabled us to perform fluorescein angiog- 50 
raphy on the same live mouse and follow the development 
and/or regression of the choroidal neovascular tufts and the 
retinal vascular blebs and lesions on successive days for the 
same mouse. A major advantage of our current in vivo assays 
is that the data can be obtained within one week. 
Effects on ROS and ROS-induced Damage 
We first performed experiments to determine ifthere actu-
ally was an increase in ROS in the retina of the VLDLr KO 
mouse and if the nanoceria could reduce the ROS and the 
damage caused by them. In a cell, the three major sources of 
intracellular ROS are from 1) mitochondrial oxidative respi-
ration, 2) NADPH-oxidase and 3) Nitrous oxide synthetase 
(NOS3). FIG. 1 shows representative data from four different 
assays (three mice for each condition for each assay) for ROS 
and ROS-induced changes. A single injection of saline or 
nanoceria (1 µl of 1 mM nanoceria) was given on P7 (7'h day 
after birth) and three weeks later the retinas were collected. 
VEGF-Western Data. 
Mice were injected intravitreally with either 1 µl of PBS or 
1 ul of PBS plus nanoceria at postnatal P13 and the animals 
killed on P21. Retinas were homogenized, subjected to SDS-
PAGE, and blotted to nitrocellulose. The bands were detected 
with primary and secondary antibodies and visualized with an 
HRP-DAB assay (FIG. 2). Wild type (+!+)retinas had barely 
detectable levels of VEGF with or without nanoceria. The 
VLDLr KO retinas had about an eightfold increase in VEGF 
compared to the +/+retinas. However, the nanoceria injected 
VLDLr KO mice had about 60% less VEGF at day 21. These 
data indicate that VEGF increased in the VLDLr KO retinas 
due to ROS and that it decreased because of the nanoceria 
mediated decrease in ROS. 
VEGF-Localization by Immunofluorescence. 
To determine where VEGF was localized in the Wild type 
and the VLD Lr KO retinas and whether the nanoceria had any 
effect on the localization, Alexa green-conjugated secondary 
antibodies were used in combination with anti-VEGF pri-
mary immunoglobulins. The wild type mouse retinas 
(C57BL/6J) (FIG. 3A,B) had very little VEGF and it was 
localized to the outer segments of the retina. However, the 
pattern oflabeling with anti-VEGF in the VLDLr KO retina 
(FIG. 3C,D) was heavy but discontinuous; predominantly in 
the outer and inner segments of photoreceptors; and espe-
55 cially in their perinuclear regions in the ONL adjacent to 
vascular lesions. The intensity of labeling progressively 
diminished as the distance from the lesion increased. The 
age-matched VLDLr mice, which had received an intravitreal 
injection (1 ul of 1 mM) of nanoceria on P7, had fewer 
60 vascular lesions and exhibited greatly reduced staining sur-
rounding the remaining lesions (FIG. 3. E, F). Individual 
"optical sections" reveal uniform labeling of the cytoplasm 
surrounding the photoreceptor cell nuclei and inner segments 
which suggests that the VLDLr KO photoreceptor cells are 
65 making VEGF. Also, a single injection of the nanoceria at P7 
inhibits the developmental increase in retinal VEGF for at 
least three weeks. These data demonstrate that the rise in 
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retinal VEGF in the VLDLr KO retina is due to ROS and can 
be prevented by the scavenging activities of nanoceria. 
Nanoceria Inhibit Development of "Neo" Leaky Retinal 
Vasculature in VLDLr KO Retinas. 
The retina has two blood supplies, the retinal vasculature 
and the choroid. The VLDLr KO retina has problems with 
both systems. The retinal vasculature of the VLDLr KO 
mouse exhibits a developmental increase in "neo" vessels 
which are absent from control retinas suggesting the possi-
bility that these vessels arise as a result of the increase in 10 
retinal VEGF and that the nanoceria can inhibit their <level-
opment. To test this, we used fluorescein-conjugated Dextran 
16 
nate the vascular anomalies which were present prior to their 
injection. To examine this possibility, we added an experi-
mental paradigm to that which is seen previously in FIG. 6. 
We also asked what would happen to the retinal blebs already 
present prior to injection. To answer this, mice were injected 
on day 28 and the vascular filling assay was done on day 35. 
The P28/35 data are shown in FIG. 8 and indicate that the 
retinal vascular lesions, blebs, have slightly increased in the 
saline injected mice but in the nanoceria injected mice the 
blebs have regressed to the same level as was found on P28 
when the mice were injected at P7. Similar data was obtained 
when the CNV blobs were counted (data not shown). These 
are especially important observations because they indicate 
that the vascular blebs and blobs present at the time of injec-
to visualize the retinal vasculature and asked if an intravitreal 
injection of the nanoceria on P7 could inhibitthe formation of 
these illicit blood vessels when visualized on P28. Represen-
tative images from such an experiment are shown in FIG. 4. 
With this assay, the larger vessels in the control C57 retinas 
(FIG. 4A) are very bright with the smaller vessels forming a 
less intensely labeled meshwork. Injection of nanoceria or 
saline has no effect on the normal retinal vasculature so that 20 
15 ti on on day 28 are dependent on the presence of ROS and their 
downstream effects. Therapeutically this means the nanoc-
eria are effective in subjects which already have vascular 
anomalies. These data also indicate that the continued pres-
ence of these illicit new blood vessels in the retinal vascula-
ture requires the continual production of ROS and that the 
"assay" for therapeutic effects can be done within a week. data is not shown. The VLDLr KO retinal vessels of saline 
injected (FIG. 4B) or uninjected (not shown) mice have 
brightly labeled newly formed vessels with coiled ends (ap-
pearing as "blebs") which project toward the RPE cells. The 
nanoceria injected VLDLr KO eyes (FIG. 4C) show greatly 
reduced numbers of these neovessels. 
In a separate parallel experiment, VEGF was quantified 
using densitometry of anti-VEGF bands on immunoblots. 
The data (FIG. 9) show that the injection of nanoceria at day 
25 28 into a mature mouse decreases by day 35 to the amount of 
retinal VEGF to that found in normal retinas. 
Results with this VLDLr KO mouse model are striking. Nanoceria Inhibit Development of Choroidal Neovascular 
Tufts. 
The vascular filling assay also enables choroidal neovas-
cular connections between the choroid and retina blood sup-
plies to be visualized. In this case, after the retina has been 
removed the remaining RPE-sclera-choroid is "pie-cut" to 
allow flat mounting and placed with the RPE facing up (FIG. 
These data demonstrate that the nanoceria down regulate 
retinal VEGF, inhibit the formation of new leaky blood ves-
30 sels in the retinal vasculature and inhibit choroidal neovascu-
larization. Our assays also enable dose response data to accu-
rately evaluate the effectiveness of different preparations of 
nanoceria. In addition, because the nanoceria were also 
shown to be therapeutic even when administered after the 
illicit retinal vessels have formed, we can now directly com-
pare the efficacy of the nanoceria over time with conventional 
treatments using anti-VEGF antibodies which are currently 
injected intravitreally every 4-6 weeks for patients with wet 
AMD. It is contemplated that nanoceria treatments are effec-
S). The pigmented RPE prevent visualization of any of the 
choroidal vasculature in the normal C57 mouse (FIG. SA) but 35 
the eyecup from the saline injected VLDLr KO mice (FIG. 
SB) had numerous bright choroidal neovascular tufts which 
projected through the RPE cell layer. However, the eyes of the 
VLDLr KO mice which had been injected with nanoceria 
(FIG. S C) have far fewer choroidal neovascular tufts. 40 tive in macular edema and diabetic retinopathy. 
Vascular Lesions can be Quantified. 
Because choroidal neovascular "tufts" and retinal neovas-
cular "blebs" are readily visible, both can be quantified. The 
results of such an experiment are presented in FIG. 6 and FIG. 
7 and demonstrate that the number of choroidal tufts present 45 
during development increases, especially by P28. The data 
also show that a single injection of nanoceria at P7 decreases 
the numberof such tufts seen in Pl 4, P21 and P28 VLDLr KO 
choroids. The confocal microscope shows the vascular 
lesions as "blebs" which are present in significant numbers 50 
even at P14 and progressively increase at P21 and P28. As 
with the tufts, the developmental appearance of the blebs is 
strongly inhibited by a single injection of nanoceria at P7. 
These data strongly support our hypothesis that ROS repre-
sents an important connection between the primary defect 55 
and the downstream effects which in the VLDLr KO mouse 
Our data demonstrate four major points. The first is that a 
single intravitreal injection of nanoceria into the eyes of 
VLDLr KO mice at Postnatal day 7 prevents the inherited 
increase in retinal ROS and ROS-mediated damage by a 
mechanism involving the inhibition of hypoxia. Our data 
show that the three major intracellular sources of ROS which 
are elevated by hypoxia, (NADPH oxidase, mitochondrial 
oxidative respiration and nitrous oxide synthetase) have 
decreased production of ROS in the presence of the nanoc-
eria. Secondly, our data show that the nanoceria, by decreas-
ing ROS, also decrease the downstream effects of ROS 
including: preventing the rise in concentration of retinal 
VEGF, the development of illicit angiogenesis within the 
retinal vasculature and the development of choroidal neovas-
cularization (CNV). The third major point is that when the 
nanoceria are injected at postnatal day 28, all of the disease 
characteristics which are present at P28 significantly regress 
(-80%) within one week. This fact provides us with an assay 
of relatively short duration (1 week) which enables the effec-
are vascular defects. These data also indicate that by counting 
blebs and tufts, the effectiveness of a therapeutic treatment 
can be evaluated. Therefore, dose response experiments can 
be done to determine the lowest dose of nanoceria that is most 
effective. This assay also enables a comparative analysis to be 
performed between nanoceria and other antioxidant agents. 
Regression of Vascular Anomalies by Treatment with 
Nanoceria. 
60 tiveness of nanoceria preparations to be evaluated within one 
week. Fourth, and most important, regarding the present 
invention, these data demonstrate that VEGF and illicit ves-
sels, present prior to administration of nanoceria decrease and 
regress when nanoceria are injected. This means that the illicit 
Although these data were scientifically very important for 
our hypothesis, from a therapeutic perspective, the nanoceria 
would be much more useful if they could decrease or elimi-
65 vessels require ROS. The normal vessels are not affected. 
This latter point is extremely important with respect to the 
therapeutic treatment of patients with RAP, AMD, diabetic 
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retinopathy or any other ROS dependent disease because 
illicit blood vessels in their eyes preferably regress after treat-
ment with the nanoceria without any negative effects on the 
normal vasculature. 
Although the present invention and its advantages have 
been described in detail, it should be understood that various 
changes, substitutions and alterations can be made herein 
without departing from the spirit and scope of the invention as 
defined by the appended claims. Moreover, the scope of the 
present application is not intended to be limited to the par- 10 
ticular embodiments of the process, compositions of matter, 
means, methods and steps described in the specification. As 
one of ordinary skill in the art will readily appreciate from the 
disclosure of the present invention, processes, compositions 
of matter, means, methods, or steps, presently existing or later 15 
to be developed that perform substantially the same function 
18 
cular tissue in the eye of the mammalian subject is substan-
tially reduced to 10% or less of that observed in the absence 
of administration of the pharmaceutical composition. 
4. The method of claim 1, wherein the at least one vascular 
anomaly is selected from the group consisting of retinal 
neovascular lesions, choroidal neovascular lesions, choroidal 
neovascular tufts, retinal neovascular blebs, and combina-
tions thereof. 
5. The method of claim 1, wherein the pathological ocular 
condition having neovascularization associated therewith is 
at least one of age-related macular degeneration, diabetic 
retinopathy, retinitis pigmentosa, retinal detachment, inher-
ited retinal degeneration, Stargardt's disease, and occlusive 
retinopathy. 
6. The method of claim 1, wherein the cerium oxide nano-
particles have a size in a range of from about 1 nanometer in 
diameter to about 10 nanometers in diameter. 
or achieve substantially the same result as the corresponding 
embodiments described herein may be utilized according to 
the present invention. Accordingly, the appended claims are 
intended to include within their scope such processes, com-
positions of matter, means, methods, or steps. 
7. The method of claim 1, wherein the cerium oxide nano-
20 particles have a size in a range of from about 1 nanometer in 
diameter to about 7 nanometers in diameter. 
Each of the references, patents or publications cited herein 
is expressly incorporated by reference in its entirety. 
What is claimed is: 
1. A method of inhibiting, reducing and/or reversing 
neovascularization associated with a pathological ocular con-
dition in a mammalian subject, the method comprising the 
steps of: 
8. The method of claim 1, wherein the cerium oxide nano-
particles are present in the pharmaceutical composition at a 
concentration in a range of from about 1 nM to about 1.0 mM. 
25 
administering a therapeutically effective amount of a phar-
maceutical composition to a mammalian subject exhib- 30 
iting neovascularization associated with a pathological 
ocular condition, the pharmaceutical composition com-
prising cerium oxide nanoparticles and a pharmaceuti-
cally acceptable carrier; and 
reducing at least one of (a) at least one vascular anomaly, 35 
(b) the number of illicit neovessels, ( c) the rate of retinal 
neovascularization, and ( d) the rate of proliferation of 
neovascular tissue in the eye of the mammalian subject 
upon administration of the cerium oxide nanoparticles 
present in the pharmaceutical composition. 40 
2. The method of claim 1, wherein the at least one vascular 
anomaly, the number of illicit neovessels, the rate of retinal 
neovascularization, and/or the rate of proliferation of neovas-
cular tissue in the eye of the mammalian subject is substan-
tially reduced to 25% or less of that observed in the absence 45 
of administration of the pharmaceutical composition. 
3. The method of claim 1, wherein the at least one vascular 
anomaly, the number of illicit neovessels, the rate of retinal 
neovascularization, and/or the rate of proliferation of neovas-
9. The method of claim 1, wherein the cerium oxide nano-
particles are present in the pharmaceutical composition at a 
concentration in a range of from about 1 nM to about 50 nM. 
10. A method of treating a mammalian subject having at 
least one neovascular lesion in an eye thereof, the method 
comprising the steps of: 
administering a therapeutically effective amount of a phar-
maceutical composition to the eye of the manmialian 
subject, the pharmaceutical composition comprising 
cerium oxide nanoparticles and a pharmaceutically 
acceptable carrier, wherein the cerium oxide nanopar-
ticles have a size in a range of from about 1 nanometer in 
diameter to about 10 nanometers in diameter and are 
present in the pharmaceutical composition at a concen-
tration in a range of from about 1 nM to about 1.0 mM; 
and 
reducing the at least one neovascular lesion in the eye of the 
mammalian subject to 50% or less of that observed in the 
absence of administration of the pharmaceutical com-
position, and wherein the at least one neovascular lesion 
is at least one of a retinal neovascular lesion and a 
choroidal neovascular lesion. 
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